Rehmann Capital Advisory Group’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Rehmann Capital Advisory Group’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-18,774	Closed	-$2.14K	–	2178
2018 Q4	$2.14K	Hold	18,774	–	–	﹤0.01%	1445
2018 Q3	$31.9K	Hold	18,774	–	–	﹤0.01%	965
2018 Q2	$32.7K	Buy	18,774 +74	+0.4%	+$128	﹤0.01%	923
2018 Q1	$34K	Hold	18,700	–	–	0.01%	902
2017 Q4	$42K	Hold	18,700	–	–	0.01%	386
2017 Q3	$54K	Hold	18,700	–	–	0.01%	375
2017 Q2	$83K	Buy	+18,700	New	+$77.1K	0.02%	371

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Rehmann Capital Advisory Group's SGYP Position: Q1 2019 in Review

Rehmann Capital Advisory Group sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 18,774 shares — an estimated $2.14K sold.

Rehmann Capital Advisory Group first reported a position in SGYP in Q2 2017 and held it in 7 quarters. The position peaked at $83K in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

Rehmann Capital Advisory Group reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 18,774 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $2.14K.
Rehmann Capital Advisory Group first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2017 and held it in 7 quarters.
Rehmann Capital Advisory Group's Synergy Pharmaceuticals, Inc Common Stock position peaked at $83K in Q2 2017.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2019, filed 22 May 2019.